ALNY
Alnylam Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.53 / 10
Netural
Money flow analysis registers 7.75/10, showing robust fund flow characteristics. Positive momentum in overall, block, and Extra-large is countered by negative tendencies in Small, Medium, and Large, suggesting positive flow conditions. Analyst consensus points to overwhelmingly bullish analyst consensus with strong conviction. Distribution analysis: Strong Buy(50.0%), Buy(25.0%), Neutral(25.0%) among 8 research opinions, supported by 3.31 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
25%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-20
InstitutionWells Fargo
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for ALNY?
- ALNY holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.53/10 (Netural).
